Bio-Matrix' Regen BioPharma Executes LOI to Acquire Issued US Patent Covering Cancer Gene-Silencing Technology for Use in Treating Breast Cancer

Validated Preclinical Technology to Be Used for Non-Toxic Treatment of Breast Cancer and Melanoma

Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN) announced today that its wholly owned subsidiary Regen BioPharma Inc. has entered into a Letter of Intent ("LOI") to purchase patented intellectual property covering a novel means of treating breast cancer by augmenting the immune system using a "gene silencing" approach.

The technology has been published in peer-reviewed journals by Professor Min, which documents its capacity of reducing tumors in melanoma (Zheng et al. J Immunol. 2006 Oct 15;177(8):5639-46) and breast cancer models (Zheng et al. Int J Cancer. 2013 Feb 15;132(4):967-77).

This gene silencing therapy was developed through over 1.5 million dollars of grant funding at the University of Western Ontario, Canada. This approach offers the possibility of destroying tumors in a non-toxic manner through leveraging the body's own immune system to recognize the cancer as "foreign" and subsequently eradicating it.